Tamarind Intelligence data continues to be an invaluable tool used by governments and NGOs around the world. In particular, Tamarind Intelligence’s most mature vertical has been recognised as a contributor to a wide number of government projects.
Data on the vaping market from ECigIntelligence is regularly used by the US Food and Drug Administration (FDA). And ECigIntelligence has also provided data to other government bodies, such as the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for two Tobacco Products Directive (TPD) impact assessments as well as Public Health England (PHE) for a report on vaping.
The devolved national government in Scotland also trusted Tamarind Intelligence as a source of data, using information from the company’s analysts as part of its Business and Regulatory Impact Assessment (BRIA) for the Health (Tobacco, Nicotine etc and Care) (Scotland) Bill.
Further data have been featured in publications by other EU member states and in Canada for Health Canada’s impact analysis on proposed vaping product promotion regulations.
And TobaccoIntelligence’s data were used in a 2021 World Health Organization (WHO) Report on the Global Tobacco Epidemic, which featured Tamarind Intelligence market analysis for heated tobacco products.
WHO knows best
Altogether the selections show the high quality and credibility of Tamarind Intelligence’s exclusive content.
“These are incredibly difficult areas to find credible and accurate data for,” said Tamarind Intelligence director Tim Phillips. “The continued use of Tamarind Intelligence data by both governments and supra-national bodies demonstrates the high degree of trust and faith in reliability both these entities and businesses in the sector place in Tamarind Intelligence’s regulatory and market analysis products.”
Can it be long before we see CannIntelligence too quoted in government and supra-national reports as cannabinoid issues continue to increase in regulatory importance?
CannIntelligence’s new broader focus on issues beyond hemp-derived CBD will also likely play a role, with assessments in areas such as intoxicating hemp-derived cannabinoids (IHDCs) plus legalisation of medical and recreational cannabis in various jurisdictions.